Clinical trials: Renal Tumors
Tuberous Sclerosis Complex
Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France
This study aims to investigate the factors (clinical, care-related and genetic) affecting renal outcome in patients with TSC (Tuberous sclerosis complex)
- Trial name
- TSAR (NCT02887781)
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Liver Neoplasms
Complicated Outcome Prediction After Liver Resection
Although mortality after liver surgery reduced during the last three decades to less than 2%, post-operative course is still complicated in a range of 20-50% of cases.The identification of one or few factors which could detect…
- Trial name
- NCT03577067
- Testing
- Liver resection for primary and secondary disease
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- University of Milan
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT06383507
- Testing
- CHT101
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- GVHD (NCT00408681)
- Testing
- lithium carbonate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Renal Cell Carcinoma
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
- Trial name
- CheckMate 9ER (NCT03141177)
- Testing
- Nivolumab, Cabozantinib, Sunitinib
- Where
- 135 sites in United States, Argentina and 16 more
- Volunteers
- 701 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated…
- Trial name
- CheckMate 374 (NCT02596035)
- Testing
- Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
To identify the maximum tolerable dose and assess qualitative/quantitative toxicities in patients with advanced renal cell cancer treated with combination of 5-azacitidine and bevacizumab.
- Trial name
- 5-AZ (NCT00934440)
- Testing
- Bevacizumab, Azacitidine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Kansas Medical Center
Kidney Tumors Treated With Minimally Invasive Surgery
Partial Nephrectomy in Low Pressure
The main objective is to prospectively assess the impact of low insufflation pressure using AirSeal system (7mm Hg) during RAPN on post-operative patient pain (main location and intensity), 24 hours after surgery.
- Trial name
- P-NeLoP (NCT05404685)
- Testing
- Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy, Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy
- Where
- 15 sites in France
- Volunteers
- 280 people
- Sponsor
- University Hospital, Bordeaux
GIST Metastatic Cancer, Breast Metastatic Cancer
Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast
RECIST criteria for evaluating tumor response are often inadequate for the evaluation of anti-angiogenic drugs. An evaluation model of tumor perfusion with contrast-enhanced ultrasonography was developed at Gustave Roussy.
- Conditions
- GIST Metastatic Cancer, Breast Metastatic Cancer, Kidney Metastatic Cancer, Colon Metastatic Cancer
- Trial name
- VARIA-DCE-US (NCT02666690)
- Testing
- CEUS (Contrast-enhanced ultrasound)
- Where
- France
- Volunteers
- 59 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and…
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04501913
- Testing
- Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Renal Cell Cancer Metastatic
Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma
The SOGUG-TIVOREAL study is a retrospective observational study with medications. This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between…
- Trial name
- SOGUG-TIVOREAL (NCT07354282)
- Where
- 14 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Bladder Carcinoma, Genitourinary System Neoplasm
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
This clinical trial evaluates light therapy and occupational therapy in improving cancer related fatigue (CRF) patients with genitourinary cancers.
- Conditions
- Bladder Carcinoma, Genitourinary System Neoplasm, Kidney Carcinoma, Prostate Carcinoma
- Trial name
- NCT05519878
- Testing
- Best Practice, Bright White Light Therapy, Occupational Therapy
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- City of Hope Medical Center
Bladder Transitional Cell Carcinoma Stage IV
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
This study is assessing the combination of well known cytotoxics with a novel anti-cancer agent that could be administered as monotherapy without renal toxicity in patients with renal impairment presenting with advanced or…
- Trial name
- JASINT1 (NCT01599013)
- Testing
- Vinflunine, Gemcitabine, Vinflunine, Carboplatin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Pierre Fabre Medicament
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone.
- Conditions
- Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma
- Trial name
- NCT04071223
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 47 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Melanoma (Skin)
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276835
- Testing
- High-dose interleukin-2, genistein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Advanced Cancer, Gastric Adenocarcinoma
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer.
- Conditions
- Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer
- Trial name
- NCT02082210
- Testing
- Emibetuzumab, Ramucirumab
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Renal Cell
Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
This observational study is conducted as part of a systematic pharmacovigilance activity, to provide a population-based context for Pazopanib use outside of the clinical trial setting.
- Trial name
- NCT01446224
- Testing
- Pazopanib, Other anti-VEGFs
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Renal Cell Carcinoma (RCC), Renal Pelvic Urothelial Carcinoma
18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
Renal cell carcinoma and renal pelvic urothelial carcinoma are common malignant tumors of the urinary system. Accurate preoperative differentiation between these tumor types is important for treatment planning, while conventional…
- Trial name
- NCT07875959
- Testing
- 18F-N230A
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University First Hospital
Renal Cell Carcinoma
Spanish Real-World Evidence Cabozantinib
RCC (Renal Cell Carcinoma) is the most common form of kidney cancer, accounting for 2-3% of all adult malignancies and for 90% of all kidney cancers.
- Trial name
- SRWEC (NCT04510688)
- Testing
- Cabozantinib
- Where
- 32 sites in Spain
- Volunteers
- 275 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.